Brokerages expect aTyr Pharma Inc (NASDAQ:LIFE) to report earnings per share (EPS) of ($0.30) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for aTyr Pharma’s earnings. The lowest EPS estimate is ($0.31) and the highest is ($0.28). aTyr Pharma reported earnings per share of ($0.43) in the same quarter last year, which indicates a positive year-over-year growth rate of 30.2%. The business is scheduled to report its next quarterly earnings results on Tuesday, November 13th.
On average, analysts expect that aTyr Pharma will report full-year earnings of ($1.29) per share for the current financial year, with EPS estimates ranging from ($1.36) to ($1.21). For the next fiscal year, analysts expect that the company will report earnings of ($1.21) per share, with EPS estimates ranging from ($1.45) to ($0.97). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for aTyr Pharma.
aTyr Pharma (NASDAQ:LIFE) last issued its earnings results on Tuesday, August 14th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01).
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of aTyr Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, July 17th. BMO Capital Markets cut their target price on shares of aTyr Pharma from $2.00 to $1.00 and set a “hold” rating on the stock in a research note on Wednesday, August 15th. Piper Jaffray Companies cut their target price on shares of aTyr Pharma from $3.00 to $1.80 and set an “overweight” rating on the stock in a research note on Monday, October 8th. Finally, Citigroup upgraded shares of aTyr Pharma from a “sell” rating to a “neutral” rating and dropped their price objective for the stock from $1.00 to $0.75 in a research note on Thursday, August 16th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. aTyr Pharma presently has a consensus rating of “Hold” and an average target price of $1.64.
In other news, CFO Jill Marie Broadfoot bought 64,000 shares of the firm’s stock in a transaction on Thursday, September 20th. The stock was purchased at an average price of $0.83 per share, for a total transaction of $53,120.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Paul Schimmel bought 164,411 shares of the firm’s stock in a transaction on Thursday, August 30th. The stock was purchased at an average price of $0.74 per share, with a total value of $121,664.14. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 297,160 shares of company stock worth $225,398. 25.00% of the stock is owned by company insiders.
An institutional investor recently raised its position in aTyr Pharma stock. Dimensional Fund Advisors LP grew its position in aTyr Pharma Inc (NASDAQ:LIFE) by 33.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 114,449 shares of the biotechnology company’s stock after purchasing an additional 28,699 shares during the period. Dimensional Fund Advisors LP owned approximately 0.38% of aTyr Pharma worth $303,000 as of its most recent SEC filing. 44.54% of the stock is owned by institutional investors.
Shares of aTyr Pharma stock traded up $0.03 during trading on Friday, reaching $0.64. The company had a trading volume of 8,590 shares, compared to its average volume of 357,725. The firm has a market cap of $19.75 million, a PE ratio of -0.34 and a beta of 2.88. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.96 and a current ratio of 5.96. aTyr Pharma has a fifty-two week low of $0.59 and a fifty-two week high of $4.60.
aTyr Pharma Company Profile
aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.
See Also: Beta
Get a free copy of the Zacks research report on aTyr Pharma (LIFE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.